Study of QLC1401 plus hormone therapy for advanced breast cancer
Part of Cancer clinical trials.
This trial tests a new drug called QLC1401 combined with standard hormone therapy for people with ER-positive, HER2-negative advanced breast cancer that is not suitable for further endocrine treatment alone. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been through menopause.
- You have been diagnosed with advanced breast cancer that is ER-positive and HER2-negative.
- You have at least one tumor that can be measured on scans (like CT or MRI).
- You are generally feeling well enough to be up and about (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within a certain range according to recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug, QLC5513, given alone or with another drug called QL1706, for people with advanced or metastatic triple-negative breast cancer (TNBC) that has worsened after at least one previous treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new drug called QL1706 combined with chemotherapy given before surgery for people with early-stage, high-risk breast cancer that is estrogen receptor positive (ER+) and HER2 negative. The goal is to see if this combination can shrink tumors more effectively before surgery.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This trial tests a new drug (QL1706) combined with hormone therapy for breast cancer that did not shrink enough with initial chemotherapy. The goal is to see if this combination can improve treatment response before surgery.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.